News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,307 Results
Type
Article (42429)
Company Profile (307)
Press Release (653571)
Section
Business (205258)
Career Advice (2012)
Deals (35575)
Drug Delivery (91)
Drug Development (81895)
Employer Resources (168)
FDA (16291)
Job Trends (14936)
News (347372)
Policy (32702)
Tag
Academia (2621)
Alliances (49660)
Alzheimer's disease (1339)
Approvals (16244)
Artificial intelligence (150)
Bankruptcy (354)
Best Places to Work (11681)
Biotechnology (218)
Breast cancer (190)
Cancer (1383)
Cardiovascular disease (110)
Career advice (1675)
Cell therapy (287)
Clinical research (65409)
Collaboration (491)
Compensation (262)
COVID-19 (2562)
C-suite (110)
Data (1401)
Diabetes (177)
Diagnostics (6196)
Earnings (85149)
Employer resources (146)
Events (111010)
Executive appointments (400)
FDA (16989)
Funding (439)
Gene therapy (204)
GLP-1 (609)
Government (4367)
Healthcare (18866)
Infectious disease (2655)
Inflammatory bowel disease (113)
Interviews (313)
IPO (16425)
Job creations (3661)
Job search strategy (1429)
Layoffs (423)
Legal (7907)
Lung cancer (199)
Manufacturing (209)
Medical device (13422)
Medtech (13427)
Mergers & acquisitions (19317)
Metabolic disorders (465)
Neuroscience (1686)
NextGen Class of 2024 (6575)
Non-profit (4519)
Northern California (1712)
Obesity (263)
Opinion (187)
Parkinson's disease (103)
Patents (120)
People (56931)
Phase I (20351)
Phase II (28817)
Phase III (21456)
Pipeline (517)
Postmarket research (2604)
Preclinical (8718)
Radiopharmaceuticals (238)
Rare diseases (270)
Real estate (5934)
Regulatory (21881)
Research institute (2387)
Resumes & cover letters (350)
Southern California (1476)
Startups (3614)
United States (15376)
Vaccines (570)
Weight loss (185)
Date
Today (126)
Last 7 days (577)
Last 30 days (2401)
Last 365 days (35652)
2024 (35494)
2023 (40410)
2022 (51555)
2021 (56102)
2020 (54418)
2019 (46966)
2018 (35382)
2017 (32512)
2016 (31995)
2015 (38010)
2014 (31764)
2013 (26991)
2012 (29094)
2011 (29659)
2010 (27715)
Location
Africa (718)
Arizona (197)
Asia (37767)
Australia (6231)
California (3856)
Canada (1459)
China (309)
Colorado (174)
Connecticut (179)
Europe (81958)
Florida (541)
Georgia (138)
Illinois (393)
Indiana (226)
Maryland (636)
Massachusetts (3020)
Michigan (179)
Minnesota (292)
New Jersey (1116)
New York (1100)
North Carolina (750)
Northern California (1712)
Ohio (147)
Pennsylvania (933)
South America (1106)
Southern California (1476)
Texas (556)
Utah (110)
Washington State (404)
696,307 Results for "alzamend neuro inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel
Alzamend Neuro, Inc. announced that the Nasdaq Hearings Panel granted Alzamend’s request to continue its listing on The Nasdaq Capital Market, subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550, which requires stockholder equity of at least $2.5 million, and satisfying all applicable requirements for continued listing on Nasdaq.
May 22, 2024
·
3 min read
Press Releases
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
December 12, 2024
·
5 min read
Press Releases
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
December 18, 2024
·
5 min read
BioMidwest
Alzamend Neuro Announces Initial Closing of Private Placement
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder, announced that it closed upon the initial tranche of a private placement pursuant to the Securities Purchase Agreement with an institutional investor.
May 14, 2024
·
5 min read
Press Releases
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
October 15, 2024
·
4 min read
BioMidwest
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
Alzamend Neuro, Inc. announced that it has terminated its “at-the-market” equity offering program relating to sales of common stock with Ascendiant Capital Markets, LLC, as sales agent.
May 7, 2024
·
3 min read
Deals
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
Alzamend Neuro, Inc. announced today that it has entered into a Securities Purchase Agreement (the “ Agreement ”) with an institutional investor (the “ Investor ”) for the purchase and sale of 50 shares of its Series A Convertible Preferred Stock.
May 9, 2024
·
6 min read
Press Releases
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
October 10, 2024
·
3 min read
Deals
Alzamend Neuro Announces Reverse Stock Split
Alzamend Neuro, Inc. today announced that Alzamend’s board of directors approved a one-for-fifteen reverse stock split of Alzamend’s common stock.
October 30, 2023
·
3 min read
Press Releases
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
November 19, 2024
·
5 min read
1 of 69,631
Next